PL
Patrick Lancuba
Staff Scientist Ii at Lumitron Technologies
View Patrick's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Staff Scientist Ii
Apr 2024 - Present · 9 months
Jan 2022 - Jan 2024 · 2 years
Staff Scientist And Coe Lead
Aug 2022 - Jan 2024 · 1 years and 5 months
R&D Scientist Iii And Coe Lead
Jan 2022 - Aug 2022 · 7 months
Company Details
51-200 Employees
Based in California, Lumitron Technologies Inc. was established to develop and commercialize unique x­‐ray systems that enable revolutionary new capabilities for ultrahigh­‐fidelity imaging, ultra­‐low dose radiography, hyper­‐precision radiotherapy, as well as element-specific and isotope-specific material identification, assay and imaging. Lumitron is pioneering a new class of high-energy, laser-Compton light sources with monochromatic, 100 keV-class x-ray outputs comparable to the those from facility-scale modern synchrotrons and monochromatic gamma-ray outputs many orders of magnitude beyond even the largest synchrotrons. For healthcare, the company intends to enable precision k-edge subtraction imaging and targeted, Auger-cascade therapy at the point of use with a form factor that will fit in existing clinical treatment environments. The technology targets vastly enhanced resolution with significant reductions in dosage enabling orders of magnitude improvement in current imaging and therapeutic modalities. Lumitron utilizes proprietary x-ray and laser technology conceived and developed at the Lawrence Livermore National Laboratory (LLNL). Lumitron holds exclusive commercial development rights to these technologies.
Year Founded
2017
Social Media
Linkedin
Industry
Medical Equipment Manufacturing
HQ Location
5201 California Avenue Suite 100 Irvine, California 92617, US
Keywords
--
Discover More About Cleveland Clinic

Find verified contacts of Patrick Lancuba in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.